| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.2012.655422 |
| P698 | PubMed publication ID | 22292483 |
| P50 | author | Fatih M. Uckun | Q89542817 |
| Sanjive Qazi | Q129085860 | ||
| P2093 | author name string | Osmond J D'Cruz | |
| Seang Yiv | |||
| P2860 | cites work | SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria | Q21144355 |
| Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women | Q24629582 | ||
| An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques | Q27438093 | ||
| Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses | Q27621483 | ||
| Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus | Q28368156 | ||
| Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus | Q28376938 | ||
| Prophylactic contraceptives for HIV/AIDS | Q28377277 | ||
| N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1 | Q28378241 | ||
| Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B | Q29618096 | ||
| Global epidemiology of HIV. | Q30353968 | ||
| Targeting early infection to prevent HIV-1 mucosal transmission. | Q30386549 | ||
| Early Events in Sexual Transmission of HIV and SIV and Opportunities for Interventions | Q30395919 | ||
| IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. | Q33210552 | ||
| Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria | Q33386027 | ||
| Comparative safety evaluation of the candidate vaginal microbicide C31G | Q33721949 | ||
| Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine | Q46230871 | ||
| Antiretroviral-drug resistance among patients recently infected with HIV. | Q46277555 | ||
| A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbamate | Q46612809 | ||
| Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial | Q46871110 | ||
| Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. | Q52549135 | ||
| Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women. | Q54733980 | ||
| Safety Study of Nonoxynol-9 as a Vaginal Microbicide: Evidence of Adverse Effects | Q57055766 | ||
| Safety and Availability of Dapivirine (TMC120) Delivered from an Intravaginal Ring | Q57847719 | ||
| Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase | Q34047516 | ||
| Foams for pharmaceutical and cosmetic application | Q34113165 | ||
| Time trends in primary HIV-1 drug resistance among recently infected persons | Q34136709 | ||
| Development of an in vitro alternative assay method for vaginal irritation | Q34414296 | ||
| Dawn of non-nucleoside inhibitor-based anti-HIV microbicides | Q34487295 | ||
| In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1 | Q34647446 | ||
| Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides | Q34737547 | ||
| Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections | Q34982527 | ||
| In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides | Q35006752 | ||
| Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides | Q35364134 | ||
| Clinical development of microbicides for the prevention of HIV infection | Q35644263 | ||
| The use of mucoadhesive polymers in vaginal delivery | Q36267061 | ||
| Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission | Q36353342 | ||
| Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission | Q36536193 | ||
| Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase | Q36632128 | ||
| Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa | Q36920232 | ||
| Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission | Q36950515 | ||
| Setting the stage: host invasion by HIV. | Q36983857 | ||
| Reverse transcriptase inhibitors as potential colorectal microbicides | Q37190754 | ||
| Conceival, a novel noncontraceptive vaginal vehicle for lipophilic microbicides | Q37360673 | ||
| HIV infection of the genital mucosa in women. | Q37370910 | ||
| Mucoadhesive vaginal drug delivery systems | Q37635263 | ||
| Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers | Q39105220 | ||
| Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group | Q39547647 | ||
| Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. | Q39634548 | ||
| Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. | Q39665893 | ||
| Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management | Q40396257 | ||
| Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor | Q40712257 | ||
| Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series | Q41110624 | ||
| Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs | Q41260272 | ||
| Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs | Q42553182 | ||
| Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. | Q43007169 | ||
| Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa | Q44811371 | ||
| Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives | Q44884891 | ||
| A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. | Q44904458 | ||
| PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide | Q45015165 | ||
| Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide | Q45423031 | ||
| Characterization of inhibitory action of concanamycins against herpes simplex virus | Q45736632 | ||
| A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe | Q46159317 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 265-279 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea]). | |
| P478 | volume | 21 |
| Q35163175 | Application of Design of Experiment and Simulation Methods to Liquid Chromatography Analysis of Topical HIV Microbicides Stampidine and HI443. |
| Q58692742 | Disubstituted 4-Chloro-3-nitrophenylthiourea Derivatives: Antimicrobial and Cytotoxic Studies |
| Q40231384 | New thiourea and 1,3-thiazolidin-4-one derivatives effective on the HIV-1 virus |
| Q38186138 | Vaginal microbicides and their delivery platforms |
Search more.